NCT07787949

Brief Summary

This study aims to compare the clinical and radiographic effectiveness of injectable platelet-rich fibrin (i-PRF) combined with minimally invasive non-surgical therapy (MINST) versus MINST alone in the management of class II furcation defects.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
6mo left

Started Mar 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
Mar 2026Mar 2027

Study Start

First participant enrolled

March 11, 2026

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

August 23, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 26, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 11, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 11, 2027

Last Updated

August 26, 2026

Status Verified

August 1, 2026

Enrollment Period

1 year

First QC Date

August 23, 2026

Last Update Submit

August 23, 2026

Conditions

Injectable Platelet-Rich FibrinMinimally InvasiveNon-Surgical TechniqueGrade II Furcation Defects

Outcome Measures

Primary Outcomes (1)

  • Change in Radiographic Bone Fill at the Furcation Site

    Radiographic bone fill at the furcation site will be assessed using cone-beam computed tomography (CBCT). The analysis will include measurement of the filled bone volume (FBV) at the furcation area using segmentation.

    6 months after treatment

Secondary Outcomes (6)

  • Change in Horizontal Clinical Attachment Level

    6 months after treatment

  • Change in Vertical Clinical Attachment Level

    6 months after treatment

  • Change in Probing Pocket Depth

    6 months after treatment

  • Change in Gingival Margin Location

    6 months after treatment

  • Change in Plaque Index

    6 months after treatment

  • +1 more secondary outcomes

Study Arms (2)

Positive control group

ACTIVE COMPARATOR

Patients will receive minimally invasive non-surgical technique (MINST) alone

Procedure: Minimally invasive non-surgical technique (MINST)

Test group

EXPERIMENTAL

Patients will receive minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection

Procedure: Minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection

Interventions

Minimally invasive non-surgical technique (MINST)PROCEDURE

Patients will receive minimally invasive non-surgical technique (MINST) alone

Positive control group
Minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injectionPROCEDURE

Patients will receive minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection

Test group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients of both genders \>18 years old, medically free of systemic diseases affecting periodontal regeneration.
  • Diagnosis of stage III, grade B periodontitis (according to the AAP/EFP classification 2018) with the presence of class II furcation defect in either the maxillary (buccal) or mandibular arch (buccal or lingual) as determined by clinical evaluation and confirmed by radiographic evaluation.
  • Gingival margin and interdental bone positioned coronally to the furcation entrance.
  • Commitment to maintenance visits and follow-up.
  • Absence of primary endodontic lesions.

You may not qualify if:

  • Patients suffering from any systemic diseases that may affect the outcome of periodontal therapy, including diabetes, immune deficiencies, etc;
  • Patients that received periodontal surgical treatments in the past 12 months.
  • Smoking (current or in past 5 years)
  • Prolonged treatment with antibiotics or anti-inflammatory agents within 6 months prior to periodontal therapy.
  • Pregnant and lactating females.
  • Teeth with hopeless prognosis
  • Third molars

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

October 6 University (Faculty of Dentistry)

Giza, Giza Governorate, 12511, Egypt

RECRUITING

MeSH Terms

Interventions

proliferation regulatory factors, human urineInjections

Intervention Hierarchy (Ancestors)

Drug Administration RoutesDrug TherapyTherapeutics

Central Study Contacts

Moustafa A Ahmed, B.D.S

CONTACT

0020109837899823110295.pg@o6u.edu.eg

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
B.D.S Faculty of Dentistry, October 6 University, Egypt

Study Record Dates

First Submitted

August 23, 2026

First Posted

August 26, 2026

Study Start

March 11, 2026

Primary Completion (Estimated)

March 11, 2027

Study Completion (Estimated)

March 11, 2027

Last Updated

August 26, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will share

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Shared Documents
STUDY PROTOCOL
Time Frame
After the end of study for one year.
Access Criteria
The data will be available upon a reasonable request from the corresponding author.

Locations

EG(1)